bTMB Analytical Validation Working Group

Mark Sausen, PhD

Senior Director, Precision Medicine Search, Evaluation & Alliances

Bristol Myers Squibb

Co-Chairs

Jonathan Baden, PhD

Executive Director, Head of Precision Medicine

Bristol Myers Squibb

Current Projects

This working group has been placed on hold as the protocols are utilized and circulate through the community. We will be returning to review any necessary additions and changes in Summer 2027.

Participating Organizations

AstraZeneca, Bristol Myers Squibb (BMS), Delfi Diagnostics, Guardant Health, Illumina, Labcorp, LGC SeraCare, Tempus

Past Deliverables

October 2025: Analytical Validation of Blood-Derived Tumor Mutation Burden (bTMB) Assays: A Joint Consensus Recommendation of the BLOODPAC bTMB Analytical Validation Working Group (manuscript in press)

Meetings

This working group has been placed on hold and is not currently accepting new members.

Special workshops and sessions:

Not applicable at this time.